“Which is better?” sounds straightforward. With Wegovy and Mounjaro, the answer depends on the outcome and the person receiving treatment. A useful comparison connects research with your health, tolerability, daily routine and ongoing expenses. A league table of weight-loss percentages cannot do that work for you.
Define what you are comparing
Wegovy contains semaglutide; Mounjaro contains tirzepatide. Both have EU weight-management indications for adults meeting specified criteria. Mounjaro also has a diabetes indication. Wegovy now includes different formulations. A comparison should therefore name the substance, formulation and treatment purpose.
Make your question more specific. Are you comparing weight change, glucose control, tolerability, fitting treatment around shift work or affordability? Different criteria may lead to different discussions. A ranking that does not explain its goal hides these distinctions.
What SURMOUNT-5 actually tested
This open-label randomised trial, published in 2025, included 751 adults with obesity without type 2 diabetes. At 72 weeks, average weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Both were injections, using specified maximum tolerated regimens.
The difference is 6.5 percentage points. It describes groups, not a guaranteed extra loss for an individual. The Eli Lilly-funded study did not compare Wegovy tablets or every treatment available today. Different outcomes or patient populations require their own relevant evidence.
Safety is not one number in a table
A list of possible adverse effects matters, but it cannot select treatment for you. Their importance also depends on existing conditions, other medicines and previous experience. Even a commonly reported symptom can be particularly burdensome for someone already struggling to eat adequately.
Compare adverse-event rates only when study conditions and reporting are comparable. Ask instead which risks matter in your case, how problems will be recognised and whom to contact. An apparently smaller percentage from two unrelated trials cannot answer those personal questions.
Consider routine and ongoing expenses together
Clarify how the prescribed form fits meals, travel and working hours. Instructions that look easy on paper may still be difficult in daily life. Ask who to contact about a missed treatment, supply problem or planned procedure rather than constructing a workaround yourself.
A cost comparison needs the same time period and your actual clinical plan. Separate the medicine pack, clinical support and any additional services. Funding can depend on country and indication. A low introductory price says little about longer-term expenditure or what is included.
Prepare a decision without prescribing for yourself
Make three columns: what matters to me, what is supported by evidence, and what needs clinical clarification. Record real constraints such as a fixed monthly budget or difficulty maintaining a particular routine. This supports a more useful shared decision.
If treatment is already working, a comparison is not a reason to switch independently. Good tolerability and achieved benefits also deserve weight in the decision. A headline about another product does not account for your history. Discuss changes with your team and keep a clear note of the agreed reasoning.
Common questions
Does the higher trial average guarantee my result?
No. Individual responses and tolerability vary. An average describes the studied group under the trial conditions, rather than predicting what will happen to you.
Can I compare the tablet trial directly with SURMOUNT-5?
You can read both, but cannot infer a direct comparison of effectiveness. Participants, control groups, duration and analysis differ. A direct comparison needs an appropriately designed trial.
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact